Categories: News

89bio to Present at the SVB Leerink 10ᵗʰ Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 5:00 PM ET.

The presentation will be available through the SVB Leerink conference portal and an archived webcast will also be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

Staff

Recent Posts

Syngene launches platform for rapid, enhanced protein production

The new proprietary cell line development platform combines a robust cell line, transposon technology with…

2 hours ago

Stanford Blood Donor Center Chooses the HemoFlow 500 and HemoVue Cloud Service to Streamline Its Whole Blood Collection Operations

GRASS VALLEY, CA / ACCESSWIRE / June 4, 2024 / Applied Science, the worldwide leader…

5 hours ago

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

7 hours ago

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

7 hours ago

AffableBPM names Greg Chavers as new Chief Revenue & Sales Officer to drive innovation in healthcare automation

SEATTLE, June 4, 2024 /PRNewswire/ -- AffableBPM, a leader in AI-powered business process automation for…

7 hours ago